ARTV

#2856
Artiva Biotherapeutics, Inc. - Common Stock
11.2 9 USD
0.00%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
11.21
11.36
Intervallo Annuale
4.07
14.53
Variazione giornaliera
-0.09%
Variazione Mensile
+12.90%
Variazione di 6 mesi
+106.40%
Variazione Annuale
+171.39%
Chiusura Precedente
11.3 0
Open
11.2 6
Minimo
11.2 1
Massimo
11.3 6
Volume
167
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Artiva Biotherapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Artiva Biotherapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Artiva Biotherapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Artiva Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Artiva Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Artiva Biotherapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Artiva Biotherapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Artiva Biotherapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Artiva Biotherapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Artiva Biotherapeutics, Inc. current report, Q1 FY2026
8-K

Artiva Biotherapeutics, Inc. current report, Q2 FY2026

Full document

Business Context and Reporting Period

Artiva Biotherapeutics, Inc. (ARTV) filed a Form 8-K on May 8, 2026, reporting the execution of an underwriting agreement for a public offering of common stock and pre-funded warrants. The company is incorporated in Delaware and operates on the Nasdaq Global Market.

Key Financial Metrics and Offering Details

  • Gross Proceeds: Approximately $300.0 million (before underwriting discounts and expenses).
  • Common Stock Issued: 23,871,526 shares at $11.52 per share.
  • Pre-Funded Warrants Issued: 2,170,138 warrants at $11.5199 per warrant.
  • Underwriters: Jefferies LLC, TD Securities (USA) LLC, and Cantor Fitzgerald & Co.
  • Expected Closing Date: May 11, 2026.

The filing does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels, as this is a current report regarding a capital raise rather than a periodic financial statement.

Material Changes and Transaction Structure

The primary material change is the planned increase in share count and capitalization through the Offering. The Pre-Funded Warrants are exercisable immediately but are subject to beneficial ownership limitations (4.99% or 9.99% caps) unless the holder provides 61 days' prior notice to increase the cap to 19.99%. The transaction is subject to customary closing conditions.

Guidance, Risks, and Contingencies

The filing contains forward-looking statements regarding the completion of the offering and the timing of the closing. The company notes that actual results may differ due to market conditions and the satisfaction of closing conditions. Specific risk factors are referenced in the Company's Form 10-Q for the quarter ended March 31, 2026. The company disclaims any obligation to update these forward-looking statements.

Investor Verification Checklist

  • Verify the final closing date and confirmation of the $300.0 million gross proceeds.
  • Review the Form 10-Q for the quarter ended March 31, 2026, for updated risk factors and current liquidity status.
  • Confirm the exact number of shares outstanding post-offering to assess dilution impact.
  • Check for any subsequent filings regarding the satisfaction of closing conditions or changes to the offering terms.